PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers

Figures & data

Figure 1. PA32540 coordinated-delivery tablet [28].

Figure 2. The pharmacokinetic release profile of omeprazole and salicylic acid from PA32540 on day 7 [28].

Figure 3. The molecular structure of aspirin.

Figure 4. The pharmacokinetics of aspirin.

Figure 5. The molecular structure of omeprazole.

Table 1. Lanza score grading system for gastrointestinal ulceration [24].

Lanza score	Description of gastrointestinal mucosa
0	No visible lesions
1	Erosion or hemorrhage
2	2–10 erosions or hemorrhages
3	11–25 erosions or hemorrhages
4	>25 erosions or hemorrhages or any ulcer

Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. Aliment Pharmacol Ther 2013;38(1):62-71

 PubMed Web of Science ®Google Scholar

Lanza FL, Aspinall RL, Swabb EA, et al. Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology 1988;95(2):289-94

 PubMed Web of Science ®Google Scholar